News & Updates

Equecabtagene autoleucel shows antitumour activity in heavily pretreated RRMM

15 Nov 2024

The fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy equecabtagene autoleucel (eque-cel) appears to induce early, deep, and lasting responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM), according to the results of the phase Ib/II FUMANBA-1 trial.

Equecabtagene autoleucel shows antitumour activity in heavily pretreated RRMM

15 Nov 2024

AD trial: Cognitive impairment exacerbated with reduced iron in brain

14 Nov 2024 by

Brain iron-lowering therapy with deferiprone appears to do more harm than good in patients with Alzheimer's disease (AD), being associated with increased cognitive decline in a phase II study.

AD trial: Cognitive impairment exacerbated with reduced iron in brain

14 Nov 2024

LSD-assisted therapy may provide lasting relief from anxiety

14 Nov 2024

People with anxiety disorders appear to obtain lasting benefits from lysergic acid diethylamide (LSD)-assisted therapy, with improved wellbeing, reduced neuroticism, and increased extraversion, as shown in a study.

LSD-assisted therapy may provide lasting relief from anxiety

14 Nov 2024

COVID-19 revisited: Where does nirmatrelvir/ritonavir fit?

14 Nov 2024

At a Pfizer-sponsored symposium held during WONCA Asia Pacific Conference 2024 in Singapore, renowned experts discussed COVID-19 vaccines and highlighted the need for effective antivirals in high-risk groups, including for older adults, with a special focus on the oral antiviral pill nirmatrelvir/ritonavir.

COVID-19 revisited: Where does nirmatrelvir/ritonavir fit?

14 Nov 2024

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

13 Nov 2024

Using atezolizumab in addition to pertuzumab plus high-dose trastuzumab does not appear to improve central nervous system (CNS) responses in HER2-positive breast cancer patients with brain metastases, according to the results of a single-arm phase II study.

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

13 Nov 2024

SGLT-2 inhibitors stop kidney stone recurrence in T2D patients with nephrolithiasis, gout

13 Nov 2024 by

Use of an SGLT-2 inhibitor, compared with a GLP-1 receptor agonist or a DPP-4 inhibitor, helps to prevent nephrolithiasis from recurring in patients with type 2 diabetes (T2D) and pre-existing nephrolithiasis or gout, as shown in target trial emulation studies.

SGLT-2 inhibitors stop kidney stone recurrence in T2D patients with nephrolithiasis, gout

13 Nov 2024

Evidence supports semaglutide for obesity-related HFpEF

13 Nov 2024 by

Semaglutide improves exercise function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) in a secondary analysis of the prespecified pooled STEP-HFpEF and STEP-HFpEF DM trials presented at HFSA 2024.

Evidence supports semaglutide for obesity-related HFpEF

13 Nov 2024

Vasopressin injection reduces bleeding, surgery time in ovarian endometrioma cystectomy

12 Nov 2024 by

In women with ovarian endometrioma, those who receive vasopressin injection during laparoscopic cystectomy experience shorter operation time, have reduced blood loss, and fewer coagulation events, as shown in a study presented at RCOG 2024.

Vasopressin injection reduces bleeding, surgery time in ovarian endometrioma cystectomy

12 Nov 2024

Faricimab trumps aflibercept in diabetic macular edema

12 Nov 2024

Treatment with faricimab demonstrates similar visual acuity and greater retinal thickness reduction, with fewer injections, when compared with aflibercept therapy in patients with diabetic macular edema (DME), reports a recent study.

Faricimab trumps aflibercept in diabetic macular edema

12 Nov 2024

Over 39M people could die from superbugs by 2050

12 Nov 2024 by

More than 39 million people worldwide could die from antibiotic-resistant infections from 2025 to 2050 as the superbug crisis intensifies, according to a new global analysis of antimicrobial resistance.

Over 39M people could die from superbugs by 2050

12 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

Equecabtagene autoleucel shows antitumour activity in heavily pretreated RRMM

Equecabtagene autoleucel shows antitumour activity in heavily pretreated RRMM

AD trial: Cognitive impairment exacerbated with reduced iron in brain

AD trial: Cognitive impairment exacerbated with reduced iron in brain

LSD-assisted therapy may provide lasting relief from anxiety

LSD-assisted therapy may provide lasting relief from anxiety

COVID-19 revisited: Where does nirmatrelvir/ritonavir fit?

COVID-19 revisited: Where does nirmatrelvir/ritonavir fit?

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

SGLT-2 inhibitors stop kidney stone recurrence in T2D patients with nephrolithiasis, gout

SGLT-2 inhibitors stop kidney stone recurrence in T2D patients with nephrolithiasis, gout

Evidence supports semaglutide for obesity-related HFpEF

Evidence supports semaglutide for obesity-related HFpEF

Vasopressin injection reduces bleeding, surgery time in ovarian endometrioma cystectomy

Vasopressin injection reduces bleeding, surgery time in ovarian endometrioma cystectomy

Faricimab trumps aflibercept in diabetic macular edema

Faricimab trumps aflibercept in diabetic macular edema

Over 39M people could die from superbugs by 2050

Over 39M people could die from superbugs by 2050